Hirudin Novel Drug Delivery Systems (NDDS)
Systematic review of hirudin novel drug delivery systems addressing the bioavailability + protease-degradation bottleneck — Mo 2024.
Mechanistic Evidence Box
Preclinical / mechanistic- Page type
- Compound profile
- Evidence type
- Systematic review of hirudin novel drug delivery systems addressing the bioavailability + protease-degradation bottleneck — Mo 2024.
- Evidence level
- Systematic review
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
NDDS-formulated hirudin is investigational. None of the novel delivery systems reviewed are FDA-approved as of publication. The K040187 medicinal-leech device clearance does NOT cover hirudin formulations.
Molecular Profile
- Category
- Anticoagulant
- Evidence tier
- Preclinical
- Source species
- Hirudo medicinalis (hirudin) + engineered carriers
- Discovered
- 2024 · Mo L et al.
Biological Targets
- → thrombin (primary mechanism); enhanced via NDDS pharmacokinetic profile
Key Citations
- Mo L et al. (2024), Int J Biol Macromol · PMID 39657884
External Resources
Related Anticoagulant Compounds
Hirudin
The most potent natural thrombin inhibitor — and the molecular template for three FDA-approved direct thrombin inhibitor drugs.
Antistasin
Factor Xa inhibitor — prototype molecule that inspired the entire DOAC drug class (rivaroxaban, apixaban).
Ghilanten
Factor Xa inhibitor with anti-metastatic activity in animal cancer models — translational dual-use compound.
Lefaxin
Factor Xa inhibitor with anti-inflammatory properties.